NCT04857138View on ClinicalTrials.gov

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions
Solid Tumors
Interventions
DRUG

RO7300490

Participants will receive RO7300490, as described in the Arm Descriptions.

DRUG

Atezolizumab

Participants will receive Atezolizumab, as described in the Arm Descriptions.

Trial Locations (11)

2100

Rigshospitalet; Fase 1 Enhed - Onkologi, København Ø

28027

Clinica Universidad de Navarra Madrid; Servicio de Oncología, Madrid

28040

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

31008

Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona

94805

Gustave Roussy, Villejuif

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

08035

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

EH4 2XU

Western General Hospital; Edinburgh Cancer Center, Edinburgh

SE1 9RT

Guys and St Thomas Hospital; OHCT Clinical Trials, London

M20 4BX

Christie Hospital NHS Trust; Experimental Cancer Medicine Team, Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY